Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 3.56

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton May 26, 2021 3:16pm

184 Views

Post# 33269248

RE:RE:3.56

Inthepez wrote: Thank you for the input, clown

YukonJezza wrote:
that's my buy target. It may make it there, it may not, but that's my buy target

External market factors can certainly cause a downward drift in the price, but quite frankly it would surprise me to see the price get down to those levels, even though it's not a drastic difference from where it is now. It would essentially be a breakdown of all technicals. I just don't see it.
In the event it did get down to that price range, I think it would be very short lived, there should be enough buying support.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks